Zacks: Brokerages Expect Eli Lilly and Co (LLY) to Post $1.16 Earnings Per Share

Brokerages expect that Eli Lilly and Co (NYSE:LLY) will post $1.16 earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Eli Lilly and’s earnings, with the highest EPS estimate coming in at $1.27 and the lowest estimate coming in at $1.10. Eli Lilly and posted earnings of $0.98 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 18.4%. The business is scheduled to issue its next quarterly earnings results before the market opens on Tuesday, April 24th.

According to Zacks, analysts expect that Eli Lilly and will report full year earnings of $4.87 per share for the current financial year, with EPS estimates ranging from $4.82 to $4.91. For the next fiscal year, analysts anticipate that the firm will report earnings of $5.29 per share, with EPS estimates ranging from $5.16 to $5.43. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Eli Lilly and.

How to Become a New Pot Stock Millionaire

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The firm had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. During the same period last year, the firm posted $0.95 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis.

LLY has been the subject of a number of research analyst reports. Jefferies Group set a $93.00 target price on Eli Lilly and and gave the stock a “buy” rating in a report on Monday, February 26th. Goldman Sachs cut Eli Lilly and from a “buy” rating to a “neutral” rating and raised their price objective for the company from $86.98 to $95.00 in a research note on Tuesday, January 16th. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and raised their price objective for the company from $85.52 to $115.00 in a research note on Friday, January 5th. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, December 5th. Finally, Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a research report on Monday, March 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $92.89.

In related news, SVP Jeffrey N. Simmons sold 9,625 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $81.12, for a total transaction of $780,780.00. Following the sale, the senior vice president now directly owns 152,120 shares in the company, valued at approximately $12,339,974.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Joshua L. Smiley sold 3,000 shares of the business’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $79.20, for a total value of $237,600.00. Following the sale, the chief financial officer now owns 20,029 shares in the company, valued at $1,586,296.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,261 shares of company stock worth $1,225,085. 0.11% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in LLY. Bank of Montreal Can increased its stake in Eli Lilly and by 85.4% in the 4th quarter. Bank of Montreal Can now owns 4,631,241 shares of the company’s stock worth $391,156,000 after acquiring an additional 2,133,606 shares during the last quarter. Investec Asset Management LTD purchased a new position in shares of Eli Lilly and in the 4th quarter worth about $163,570,000. Janus Henderson Group PLC boosted its holdings in shares of Eli Lilly and by 16.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock worth $928,719,000 after purchasing an additional 1,503,918 shares in the last quarter. Schroder Investment Management Group boosted its holdings in shares of Eli Lilly and by 81.3% in the 4th quarter. Schroder Investment Management Group now owns 2,300,675 shares of the company’s stock worth $194,315,000 after purchasing an additional 1,031,859 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. boosted its holdings in shares of Eli Lilly and by 110.9% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 1,832,626 shares of the company’s stock worth $154,783,000 after purchasing an additional 963,776 shares in the last quarter. Institutional investors own 77.63% of the company’s stock.

Shares of LLY stock traded down $1.35 during mid-day trading on Wednesday, reaching $76.02. 3,050,021 shares of the stock traded hands, compared to its average volume of 4,879,274. Eli Lilly and has a 1-year low of $73.69 and a 1-year high of $89.09. The firm has a market capitalization of $84,766.41, a price-to-earnings ratio of 17.76, a PEG ratio of 1.41 and a beta of 0.26. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85.

TRADEMARK VIOLATION WARNING: This news story was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.wkrb13.com/2018/04/02/zacks-brokerages-expect-eli-lilly-and-co-lly-to-post-1-16-earnings-per-share.html.

About Eli Lilly and

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply